cancer

ASCO and Friends of Cancer Research Draft 5 Guidances for FDA
ASCO and Friends of Cancer Research Draft 5 Guidances for FDA
RAPS.org
ASCO
FDA
cancer
oncology
clinical trials
Friends of Cancer Research
Flag link:
Better U.S. Patient Access To Cancer Drugs Comes At A Price
Better U.S. Patient Access To Cancer Drugs Comes At A Price
Forbes
cancer
Europe
patient access
patients
reimbursement
drug pricing
Flag link:
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Forbes
Regeneron
Bluebird Bio
CAR-T
drug discovery
gene therapy
cancer
Flag link:
Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech
Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech
Fierce Biotech
Novartis
China
Laekna
cancer
afuresertib
uprosertib
Flag link:
Days after Merck deal, Sutro rolls out $85M E round to fund internal cancer pipeline
Days after Merck deal, Sutro rolls out $85M E round to fund internal cancer pipeline
Endpoints
Sutro BioPharma
cancer
Merck
Flag link:
The Real Future Of Artificial Intelligence And Cancer
The Real Future Of Artificial Intelligence And Cancer
Forbes
cancer
artificial intelligence
CogX
Flag link:
Bristol-Myers Squibb and Gritstone Oncology Announce Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Bristol-Myers Squibb and Gritstone Oncology Announce Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
CP Wire
Bristol-Myers Squibb
Gritstone Oncology
Opdivo
Yervoy
GRANITE-001
cancer
Flag link:
Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program
Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program
Endpoints
Sanofi
Revolution Medicines
cancer
Flag link:
Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology
Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology
BioSpace
Presage Biosciences
Takeda
Celgene
cancer
diagnostics
Flag link:
Ascentage third round garners $150M for apoptosis cancer drugs
Ascentage third round garners $150M for apoptosis cancer drugs
Fierce Biotech
Ascentage
China
apoptosis
cancer
Flag link:
Keep Your Eyes on Healthcare's Odd Couple: AbbVie and Alphabet
Keep Your Eyes on Healthcare's Odd Couple: AbbVie and Alphabet
Motley Fool
AbbVie
Calico
Alphabet
age-related disease
cancer
drug development
Flag link:
CRISPR makes cancer cells turncoats that attack their tumor, mouse study finds
CRISPR makes cancer cells turncoats that attack their tumor, mouse study finds
Stat
CRISPR
cancer
gene editing
Flag link:
Hitting cancer early: AstraZeneca's bid to outmaneuver rivals
Hitting cancer early: AstraZeneca's bid to outmaneuver rivals
Yahoo/Reuters
AstraZeneca
Pascal Soriot
cancer
Imfinzi
Flag link:
Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug
Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug
CP Wire
Argenx
AbbVie
ARGX-115
cancer
Flag link:
Naturally-Derived Cancer Drugs Provide Clues As To How Microbiome May Cause Chemotherapy Resistance
Naturally-Derived Cancer Drugs Provide Clues As To How Microbiome May Cause Chemotherapy Resistance
Forbes
Pfizer
Mylotarg
Besponsa
chemotherapy
cancer
microbiome
Flag link:
Latecomer Sanofi looks to catch next wave of cancer therapies
Latecomer Sanofi looks to catch next wave of cancer therapies
Reuters
Sanofi
cancer
immuno-oncology
oncology
Flag link:
Finding Cancer Patients Is the Pharma Industry’s Unlikely Challenge
Finding Cancer Patients Is the Pharma Industry’s Unlikely Challenge
Bloomberg
patients
cancer
Bayer
Roche
diagnostics
Flag link:
Is ASCO Sending Mixed Messages On Cancer Drug Value?
Is ASCO Sending Mixed Messages On Cancer Drug Value?
Forbes
ASCO
cancer
oncology
value
drug pricing
Flag link:
Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
Reuters
biotech
IPOs
cancer
Nant
Patrick Soon-Shiong
Flag link:
A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies
A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies
Stat
CRISPR
gene editing
cancer
Flag link:

Pages